BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4). These included long-term (52-week) analyses from the PALACE 1, 2 and 3 trials of the impact of OTEZLA on psoriatic arthritis disease activity, safety and tolerability, in addition to a separate 16-week work productivity analysis from PALACE 1. The findings were presented at the European League Against Rheumatism Annual Congress (EULAR 2014) in Paris, France.
Help employers find you! Check out all the jobs and post your resume.
